{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T09:38:51Z","timestamp":1794649131606,"version":"4.9.1"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T00:00:00Z","timestamp":1782777600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T00:00:00Z","timestamp":1782777600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100014387","name":"ACADIA Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014387","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1007\/s12325-026-03686-1","type":"journal-article","created":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T17:59:46Z","timestamp":1782842386000},"page":"4458-4472","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Real-World Demographics, Clinical Characteristics, and Predictors of Persistence Among Males with Rett Syndrome Treated with Trofinetide"],"prefix":"10.1007","volume":"43","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4878-0822","authenticated-orcid":false,"given":"Krithika","family":"Rajagopalan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-1576-0977","authenticated-orcid":false,"given":"Vinod","family":"Yakkala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4227-1234","authenticated-orcid":false,"given":"Nazia","family":"Rashid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,30]]},"reference":[{"issue":"2","key":"3686_CR1","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1038\/13810","volume":"23","author":"RE Amir","year":"1999","unstructured":"Amir RE, Van den Veyver IB, Wan M, Tran CQ, Francke U, Zoghbi HY. Rett syndrome is caused by mutations in X-linked MECP2, encoding methyl-CpG-binding protein 2. Nat Genet. 1999;23(2):185\u20138. https:\/\/doi.org\/10.1038\/13810.","journal-title":"Nat Genet"},{"issue":"3","key":"3686_CR2","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1016\/j.neuron.2007.10.001","volume":"56","author":"M Chahrour","year":"2007","unstructured":"Chahrour M, Zoghbi HY. The story of Rett syndrome: from clinic to neurobiology. Neuron. 2007;56(3):422\u201337. https:\/\/doi.org\/10.1016\/j.neuron.2007.10.001.","journal-title":"Neuron"},{"issue":"6","key":"3686_CR3","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1002\/ana.22124","volume":"68","author":"JL Neul","year":"2010","unstructured":"Neul JL, Kaufmann WE, Glaze DG, et al. Rett syndrome: revised diagnostic criteria and nomenclature. Ann Neurol. 2010;68(6):944\u201350. https:\/\/doi.org\/10.1002\/ana.22124.","journal-title":"Ann Neurol"},{"issue":"7","key":"3686_CR4","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1136\/jmg.2007.049452","volume":"44","author":"L Villard","year":"2007","unstructured":"Villard L. MECP2 mutations in males. J Med Genet. 2007;44(7):417\u201323. https:\/\/doi.org\/10.1136\/jmg.2007.049452.","journal-title":"J Med Genet"},{"issue":"8","key":"3686_CR5","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1001\/archneurol.2011.149","volume":"68","author":"AK Percy","year":"2011","unstructured":"Percy AK. Rett syndrome: exploring the autism link. Arch Neurol. 2011;68(8):985\u20139. https:\/\/doi.org\/10.1001\/archneurol.2011.149.","journal-title":"Arch Neurol"},{"issue":"5","key":"3686_CR6","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1016\/j.pediatrneurol.2015.06.003","volume":"53","author":"DC Tarquinio","year":"2015","unstructured":"Tarquinio DC, Hou W, Neul JL, et al. The changing face of survival in Rett syndrome and MECP2-related disorders. Pediatr Neurol. 2015;53(5):402\u201311. https:\/\/doi.org\/10.1016\/j.pediatrneurol.2015.06.003.","journal-title":"Pediatr Neurol"},{"issue":"6","key":"3686_CR7","doi-asserted-by":"publisher","first-page":"1468","DOI":"10.1038\/s41591-023-02398-1","volume":"29","author":"JL Neul","year":"2023","unstructured":"Neul JL, Percy AK, Benke TA, et al. Trofinetide for the treatment of Rett syndrome: a randomized phase\u00a03 study. Nat Med. 2023;29(6):1468\u201375. https:\/\/doi.org\/10.1038\/s41591-023-02398-1.","journal-title":"Nat Med"},{"key":"3686_CR8","unstructured":"Center for Drug Evaluation and Research. FDA approves first treatment for Rett Syndrome. FDA. Published online March 20, 2023. https:\/\/www.fda.gov\/drugs\/news-events-human-drugs\/fda-approves-first-treatment-rett-syndrome. Accessed 20 Apr 2026"},{"issue":"9","key":"3686_CR9","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1007\/s40265-023-01883-8","volume":"83","author":"SJ Keam","year":"2023","unstructured":"Keam SJ. Trofinetide: first approval. Drugs. 2023;83(9):819\u201324. https:\/\/doi.org\/10.1007\/s40265-023-01883-8.","journal-title":"Drugs"},{"issue":"9","key":"3686_CR10","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.1016\/j.medj.2024.05.018","volume":"5","author":"AK Percy","year":"2024","unstructured":"Percy AK, Neul JL, Benke TA, et al. Trofinetide for the treatment of Rett syndrome: results from the open-label extension LILAC study. Med. 2024;5(9):1178-1189.e3. https:\/\/doi.org\/10.1016\/j.medj.2024.05.018.","journal-title":"Med"},{"issue":"10","key":"3686_CR11","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1016\/j.medj.2024.06.007","volume":"5","author":"AK Percy","year":"2024","unstructured":"Percy AK, Neul JL, Benke TA, et al. Trofinetide for the treatment of Rett syndrome: long-term safety and efficacy results of the 32-month, open-label LILAC-2 study. Med. 2024;5(10):1275\u201381. https:\/\/doi.org\/10.1016\/j.medj.2024.06.007.","journal-title":"Med"},{"issue":"6","key":"3686_CR12","doi-asserted-by":"publisher","DOI":"10.1016\/j.medj.2025.100608","volume":"6","author":"AK Percy","year":"2025","unstructured":"Percy AK, Ryther R, Marsh ED, et al. Results from the phase\u00a02\/3 DAFFODIL study of trofinetide in girls aged 2-4\u00a0years with Rett syndrome. Med. 2025;6(6):100608. https:\/\/doi.org\/10.1016\/j.medj.2025.100608.","journal-title":"Med"},{"issue":"1","key":"3686_CR13","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1007\/s40261-023-01322-2","volume":"44","author":"M Darwish","year":"2024","unstructured":"Darwish M, Nunez R, Youakim JM, Robertson P Jr. Characterization of the pharmacokinetics and mass balance of a single oral dose of trofinetide in healthy male subjects. Clin Drug Investig. 2024;44(1):21\u201333. https:\/\/doi.org\/10.1007\/s40261-023-01322-2.","journal-title":"Clin Drug Investig"},{"issue":"1","key":"3686_CR14","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1007\/s13318-024-00924-1","volume":"50","author":"M Darwish","year":"2025","unstructured":"Darwish M, Marbury TC, Nunez R, et al. Physiologically-based pharmacokinetic modeling of trofinetide in moderate renal impairment for phase\u00a01 clinical study dose selection with model validation. Eur J Drug Metab Pharmacokinet. 2025;50(1):23\u201338. https:\/\/doi.org\/10.1007\/s13318-024-00924-1.","journal-title":"Eur J Drug Metab Pharmacokinet"},{"issue":"9","key":"3686_CR15","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1007\/s10654-022-00898-x","volume":"37","author":"F Tian","year":"2022","unstructured":"Tian F, Fang F, Shen Q, Ye W, Valdimarsd\u00f3ttir UA, Song H. Stress-related disorders and subsequent cancer risk and mortality: a population-based and sibling-controlled cohort study in Sweden. Eur J Epidemiol. 2022;37(9):947\u201358. https:\/\/doi.org\/10.1007\/s10654-022-00898-x.","journal-title":"Eur J Epidemiol"},{"issue":"1","key":"3686_CR16","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1186\/s12872-016-0202-x","volume":"16","author":"CF Lin","year":"2016","unstructured":"Lin CF, Chang YH, Liu JC, Chuang MT, Chien LN. Statin use associated with a reduced risk of pneumonia requiring hospitalization in patients with myocardial infarction: a nested case-control study. BMC Cardiovasc Disord. 2016;16(1):24. https:\/\/doi.org\/10.1186\/s12872-016-0202-x.","journal-title":"BMC Cardiovasc Disord"},{"issue":"1","key":"3686_CR17","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1186\/s12883-023-03181-y","volume":"23","author":"D May","year":"2023","unstructured":"May D, Kponee-Shovein K, Mahendran M, et al. Epidemiology and patient journey of Rett syndrome in the United States: a real-world evidence study. BMC Neurol. 2023;23(1):141. https:\/\/doi.org\/10.1186\/s12883-023-03181-y.","journal-title":"BMC Neurol"},{"key":"3686_CR18","unstructured":"Rashid N, Yakkala V, Gopal D, Rajagopalan K, et al. Epilepsy Rates Among Individuals Treated versus Untreated with Trofinetide for Rett Syndrome in the United States. Presented at: American Epilepsy Society Annual Meeting; December 6\u20138, 2025; Atlanta, GA, USA. https:\/\/acadia.com\/en-us\/pdf\/healthcare-professionals\/scientific-publications\/congress-materials\/2025_AES_Rajagopalan_Demographic__Clinical_Characteristics_Adults_Pos.pdf. Accessed 28 Apr 2026"},{"key":"3686_CR19","doi-asserted-by":"publisher","DOI":"10.2217\/frd-2022-0023","author":"T Davis","year":"2023","unstructured":"Davis T, Parab P, May D, Ruetsch C. Understanding characteristics, conditions and treatment patterns among males diagnosed with Rett syndrome: an analysis of commercial health insurance claims. Future Rare Dis. 2023. https:\/\/doi.org\/10.2217\/frd-2022-0023.","journal-title":"Future Rare Dis"},{"key":"3686_CR20","doi-asserted-by":"publisher","DOI":"10.1080\/23995270.2025.2597031","author":"E Prange","year":"2025","unstructured":"Prange E, Lieberman D, Correa G, et al. Real-world use of trofinetide: a survey of practices from prescribers at Rett syndrome centers of excellence in the United States. Future Rare Dis. 2025. https:\/\/doi.org\/10.1080\/23995270.2025.2597031.","journal-title":"Future Rare Dis"},{"key":"3686_CR21","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1002\/cns3.70062","volume":"4","author":"E Prange","year":"2026","unstructured":"Prange E, Beisang A, Pehlivan D, et al. Expert consensus on real-world use of trofinetide for Rett syndrome using a modified Delphi method. Ann Child Neurol Soc. 2026;4:38\u201351. https:\/\/doi.org\/10.1002\/cns3.70062.","journal-title":"Ann Child Neurol Soc"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-026-03686-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-026-03686-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-026-03686-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T04:14:42Z","timestamp":1790655282000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-026-03686-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,30]]},"references-count":21,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["3686"],"URL":"https:\/\/doi.org\/10.1007\/s12325-026-03686-1","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,30]]},"assertion":[{"value":"16 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Krithika Rajagopalan and Vinod Yakkala are current employees of Anlitiks Inc., a company that received funding from Acadia Pharmaceuticals to conduct this study. Nazia Rashid is a current employees of Acadia Pharmaceuticals based in San Diego, CA, USA.","order":1,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"As\u00a0this study involves deidentified, anonymized, patient level secondary data from other claims data sources without containing any identifiable protected health information (PHI) in accordance with HIPAA Security Act of 1996, patient consent was not required, and the need for ethics committee approval was not applicable.","order":2,"name":"Ethics","label":"Ethical Approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}